StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
| Metric | Q1 2014 2014-03-31 |
|---|---|
Revenue | $22.00K |
Operating Income | $-11.88M |
Net Income | $-10.75M |
EPS (Diluted) | Not available |
Total Assets | $55.61M |
Total Liabilities | Not available |
Cash & Equivalents | $46.04M |
Free Cash Flow OCF − CapEx | $-10.17M |
Shares Outstanding | 606.24K |
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-13 | $11.51 | $12.95 | +12.51% | 0.5M |
| 05-14 | $13.00 | $12.65 | -2.65% | 0.2M |
| 05-15 | $12.36 | $12.08 | -2.27% | 0.2M |
| 05-18 | $12.10 | $11.66 | -3.64% | 0.1M |
| 05-19 | $11.77 | $11.50 | -2.29% | 0.0M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.